Cellsway
Innovative liquid biopsy solutions for efficient cancer cell detection and patient profiling.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €1.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Cellsway is a pioneering startup in the field of cancer diagnostics, focusing on the development and commercialization of advanced liquid biopsy technologies. The company operates in the healthcare and biotechnology market, specifically targeting oncology professionals, research institutions, and clinical laboratories.
Cellsway's flagship product is the CTC Enrichment Chip, a patented technology designed to efficiently isolate circulating tumor cells (CTCs) from blood samples. This technology is crucial for cancer management as it allows for minimally invasive sampling, enabling better patient profiling and monitoring. The CTC Enrichment Chip is complemented by a suite of products, including the ER PR Her2 CTC Panel and the CTC Identification Panel. These panels facilitate the detection of specific cancer markers such as Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) through immunofluorescence analysis, which is a method that uses antibodies and fluorescent dyes to detect specific proteins in cells.
Cellsway's business model is centered around selling these diagnostic kits and devices to service laboratories and healthcare providers. The company generates revenue through the direct sale of its products and potentially through service agreements with laboratories that utilize its technology for patient testing. The CTC Enrichment Device, another key product, is a fully automated instrument that simplifies the process of CTC isolation, requiring only 10 minutes of hands-on time, making it user-friendly and efficient for laboratory use.
In summary, Cellsway is revolutionizing cancer diagnostics with its cutting-edge liquid biopsy technology, providing tools that enhance the detection and monitoring of cancer through simple blood tests. This approach not only improves patient outcomes but also supports ongoing cancer research and personalized treatment strategies.
Keywords: Liquid Biopsy, Cancer Diagnostics, CTC Enrichment, Oncology, Immunofluorescence, Patient Profiling, Automated Instrument, Healthcare, Biotechnology, Cancer Markers.